表紙:融合生検の市場動向・市場シェア・市場規模の予測 (2021-2028年):生検ルート (経直腸・経会陰)・エンドユーザー (病院・診断センター・外来診療センター)・地域別
市場調査レポート
商品コード
1026802

融合生検の市場動向・市場シェア・市場規模の予測 (2021-2028年):生検ルート (経直腸・経会陰)・エンドユーザー (病院・診断センター・外来診療センター)・地域別

Fusion Biopsy Market Size, Share & Trends Analysis Report By Biopsy Route (Transrectal, Transperineal), By End-use (Hospitals, Diagnostic Centers, Ambulatory Care Centers), By Region, And Segment Forecasts, 2021 - 2028

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 100 Pages | 納期: 2-10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.08円
融合生検の市場動向・市場シェア・市場規模の予測 (2021-2028年):生検ルート (経直腸・経会陰)・エンドユーザー (病院・診断センター・外来診療センター)・地域別
出版日: 2021年08月31日
発行: Grand View Research, Inc.
ページ情報: 英文 100 Pages
納期: 2-10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の融合生検の市場規模は予測期間中11.6%のCAGRで推移し、2028年には11億1000万米ドルの規模に成長すると予測されています。

前立腺癌の有病率の増加、標的生検の需要の高まり、前立腺癌治療におけるマルチパラメトリックMRIの利用率の上昇などの要因が予測期間中の市場を牽引すると予測されています。

MRI・超音波融合生検は、TRUS生検、PSA検査、直腸指診などの従来技術と比較して、前立腺病変の描出において高い感度と特異性を有しており、市場成長に貢献すると期待されています。また、侵攻性腫瘍の診断における信頼性と再現性から、融合生検システムは前立腺生検における標準的なツールになると期待されています。

当レポートでは、世界の融合生検の市場を調査し、市場の定義と概要、バリューチェーン、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、償還環境、市場規模の推移・予測、生検ルート・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 市場可変因子・動向・展望

  • 市場の見通し
  • 普及・成長の見通しマッピング
  • バリューチェーン分析
  • 市場力学
  • 市場分析ツール

第4章 市場分析・予測:生検ルート別

  • 経直腸
  • 経会陰

第5章 市場分析・予測:エンドユーザー別

  • 病院
  • 診断センター
  • 外来診療センター

第6章 市場分析・予測:地域・主要国別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第7章 競合情勢

  • 主要企業・近年の展開・影響分析
  • 主要企業・競合上の分類
  • ベンダー情勢
  • 公開企業
  • 非公開企業
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America fusion biopsy market, by region, 2016 - 2028 (USD Million)
  • Table 3 North America fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 4 North America fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 5 U.S. fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 6 U.S. fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 7 Canada fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 8 Canada fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 9 Europe fusion biopsy market, by region, 2016 - 2028 (USD Million)
  • Table 10 Europe fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 11 Europe fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 12 U.K. fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 13 U.K. fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 14 Germany fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 15 Germany fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 16 Italy fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 17 Italy fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 18 France fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 19 France fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 20 Spain fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 21 Spain fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 22 Switzerland fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 23 Switzerland fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 24 Belgium fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 25 Belgium fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 26 Asia Pacific fusion biopsy market, by region, 2016 - 2028 (USD Million)
  • Table 27 Asia Pacific fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 28 Asia Pacific fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 29 Japan fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 30 Japan fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 31 India fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 32 India fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 33 China fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 34 China fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 35 Thailand fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 36 Thailand fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 37 South Korea fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 38 South Korea fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 39 Australia fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 40 Australia fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 41 Latin America fusion biopsy market, by region, 2016 - 2028 (USD Million)
  • Table 42 Latin America fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 43 Latin America fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 44 Brazil fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 45 Brazil fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 46 Mexico fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 47 Mexico fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 48 Argentina fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 49 Argentina fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 50 MEA fusion biopsy market, by region, 2016 - 2028 (USD Million)
  • Table 51 MEA fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 52 MEA fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 53 South Africa fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 54 South Africa fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 55 Saudi Arabia fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 56 Saudi Arabia fusion biopsy market, by end use, 2016 - 2028 (USD Million)
  • Table 57 UAE fusion biopsy market, by biopsy route, 2016 - 2028 (USD Million)
  • Table 58 UAE fusion biopsy market, by end use, 2016 - 2028 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Fusion biopsy market: market outlook
  • Fig. 14 Fusion biopsy market competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Fusion biopsy market driver impact
  • Fig. 20 Fusion biopsy market restraint impact
  • Fig. 21 Fusion biopsy market strategic initiatives analysis
  • Fig. 22 Fusion biopsy market: biopsy route movement analysis
  • Fig. 23 Fusion biopsy market: biopsy route outlook and key takeaways
  • Fig. 24 Transrectal market estimates and forecast, 2016 - 2028
  • Fig. 25 Transperineal market estimates and forecast, 2016 - 2028
  • Fig. 26 Fusion biopsy market: end-use movement analysis
  • Fig. 27 Fusion biopsy market: end-use outlook and key takeaways
  • Fig. 28 Hospitals market estimates and forecast, 2016 - 2028
  • Fig. 29 Diagnostic centers market estimates and forecast, 2016 - 2028
  • Fig. 30 Ambulatory care centers market estimates and forecast, 2016 - 2028
  • Fig. 31 Fusion biopsy market: regional movement analysis
  • Fig. 32 Fusion biopsy market: regional outlook and key takeaways
  • Fig. 33 Fusion biopsy market share and leading players
  • Fig. 34 North America market share and leading players
  • Fig. 35 Europe market share and leading players
  • Fig. 36 Asia Pacific market share and leading players
  • Fig. 37 Latin America market share and leading players
  • Fig. 38 Middle East & Africa market share and leading players
  • Fig. 39 North America: SWOT
  • Fig. 40 Europe SWOT
  • Fig. 41 Asia Pacific SWOT
  • Fig. 42 Latin America SWOT
  • Fig. 43 MEA SWOT
  • Fig. 44 North America, by country
  • Fig. 45 North America
  • Fig. 46 North America market estimates and forecast, 2016 - 2028
  • Fig. 47 U.S.
  • Fig. 48 U.S. market estimates and forecast, 2016 - 2028
  • Fig. 49 Canada
  • Fig. 50 Canada market estimates and forecast, 2016 - 2028
  • Fig. 51 Europe
  • Fig. 52 Europe market estimates and forecast, 2016 - 2028
  • Fig. 53 U.K.
  • Fig. 54 U.K. market estimates and forecast, 2016 - 2028
  • Fig. 55 Germany
  • Fig. 56 Germany market estimates and forecast, 2016 - 2028
  • Fig. 57 France
  • Fig. 58 France market estimates and forecast, 2016 - 2028
  • Fig. 59 Italy
  • Fig. 60 Italy market estimates and forecast, 2016 - 2028
  • Fig. 61 Spain
  • Fig. 62 Spain market estimates and forecast, 2016 - 2028
  • Fig. 63 Switzerland
  • Fig. 64 Switzerland market estimates and forecast, 2016 - 2028
  • Fig. 65 Belgium
  • Fig. 66 Belgium market estimates and forecast, 2016 - 2028
  • Fig. 67 Asia Pacific
  • Fig. 68 Asia Pacific market estimates and forecast, 2016 - 2028
  • Fig. 69 China
  • Fig. 70 China market estimates and forecast, 2016 - 2028
  • Fig. 71 Japan
  • Fig. 72 Japan market estimates and forecast, 2016 - 2028
  • Fig. 73 India
  • Fig. 74 India market estimates and forecast, 2016 - 2028
  • Fig. 75 Thailand
  • Fig. 76 Thailand market estimates and forecast, 2016 - 2028
  • Fig. 77 South Korea
  • Fig. 78 South Korea market estimates and forecast, 2016 - 2028
  • Fig. 79 Australia
  • Fig. 80 Australia market estimates and forecast, 2016 - 2028
  • Fig. 81 Latin America
  • Fig. 82 Latin America market estimates and forecast, 2016 - 2028
  • Fig. 83 Brazil
  • Fig. 84 Brazil market estimates and forecast, 2016 - 2028
  • Fig. 85 Mexico
  • Fig. 86 Mexico market estimates and forecast, 2016 - 2028
  • Fig. 87 Argentina
  • Fig. 88 Argentina market estimates and forecast, 2016 - 2028
  • Fig. 89 Middle East and Africa
  • Fig. 90 Middle East and Africa. market estimates and forecast, 2016 - 2028
  • Fig. 91 South Africa
  • Fig. 92 South Africa market estimates and forecast, 2016 - 2028
  • Fig. 93 Saudi Arabia
  • Fig. 94 Saudi Arabia market estimates and forecast, 2016 - 2028
  • Fig. 95 UAE
  • Fig. 96 UAE market estimates and forecast, 2016 - 2028
  • Fig. 97 Participant categorization- fusion biopsy market
  • Fig. 98 Market share of key market players- fusion biopsy market
目次
Product Code: GVR-4-68038-844-2

Fusion Biopsy Market Growth & Trends:

The global fusion biopsy market size is estimated to reach USD 1.11 billion by 2028 registering a CAGR of 11.6%, according to a new report by Grand View Research, Inc. The increasing prevalence of prostate cancer, growing demand for targeted biopsy, and the rising utilization rate of multiparametric MRI in prostate cancer care are factors expected to drive the market during the forecast period.

High sensitivity and specificity of targeted MR/Ultrasound fusion biopsy in delineating prostate lesions compared to other traditional technologies such as TRUS biopsy, PSA test, or Digital Rectal Examination is expected to contribute to the market growth. The reliability and reproducibility of the fusion biopsy system in the diagnosis of aggressive tumors is expected to make it a standard tool in prostate biopsy.

An increasing number of radiologists gaining expertise in interpreting prostate MRI coupled with the implementation of standard image grading systems such as PI-RADS and Gleason score has increased the utilization rate of targeted MR/Ultrasound fusion biopsy systems.

The increasing number of government initiatives in terms of funding research, spreading awareness, and conducting mass screening programs related to prostate cancer are expected to play a crucial in the growth of the market. Some of the growth strategies adopted by market players include partnership, product launch, participation in trade events and conferences, and acquisitions to sustain in this highly competitive market.

Fusion Biopsy Market Report Highlights:

  • The transrectal segment held the largest market share in 2019, as it is the gold standard and commonly used method of prostate fusion biopsy
  • The transperineal segment is expected to grow at the fastest rate during the forecast period owing to the safety, diagnostic efficiency, and ability to access the ventral prostate areas
  • The hospital segment accounted for the largest revenue share in 2019 because of the factors such as increasing the procurement rate of MR/US targeted fusion biopsy systems in teaching hospitals
  • The diagnostics centers segment is expected to grow at a significant rate over the forecast period. Shorter wait times, cost efficiency, and developing reimbursement paradigm are the factors expected to drive the growth of this segment
  • North America held the largest market share in the market in 2019 and is anticipated to maintain its dominance over the forecast period
  • Asia Pacific is anticipated to witness a CAGR of 10.5% during the forecast period owing to factors such as growing awareness about the sensitivity and specificity of MRI/US targeted fusion biopsy systems among urologists especially in countries such as Japan, Australia, and China.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Biopsy route
    • 1.1.2. End-use
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Biopsy route outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Fusion Biopsy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
    • 3.3.1. Reimbursement framework
  • 3.4. Market Dynamics
    • 3.4.1. Market driver analysis
      • 3.4.1.1. Increasing prevalence of prostate cancer
      • 3.4.1.2. Technological advancements in fusion imaging modalities
      • 3.4.1.3. Increasing funds and investments by public and private sector
    • 3.4.2. Market restraint analysis
      • 3.4.2.1. High cost of fusion biopsy system
      • 3.4.2.2. Liquid biopsy system
  • 3.5. Fusion Biopsy Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic landscape
    • 3.5.3. Major deals & strategic alliances analysis
    • 3.5.4. Market entry strategies
    • 3.5.5. Covid-19 Impact Analysis

Chapter 4. Fusion Biopsy Market: Biopsy Route Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Transrectal
    • 4.1.2. Transperineal
  • 4.2. Biopsy Route Market Share, 2020 & 2028
  • 4.3. Segment Dashboard
  • 4.4. Global Fusion Biopsy Market by Biopsy Route Outlook
  • 4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
    • 4.5.1. Transrectal
      • 4.5.1.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 4.5.2. Transperineal
      • 4.5.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)

Chapter 5. Fusion Biopsy Market: End-use Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Hospitals
    • 5.1.2. Diagnostic centers
    • 5.1.3. Ambulatory care centers
  • 5.2. End-use, 2020 & 2028
  • 5.3. Segment Dashboard
  • 5.4. Fusion Biopsy Market By End Use Outlook
  • 5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
    • 5.5.1. Hospitals
      • 5.5.1.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 5.5.2. Diagnostic Centers
      • 5.5.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 5.5.3. Ambulatory Care Centers
      • 5.5.3.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)

Chapter 6. Fusion Biopsy Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2020 & 2028
  • 6.2. Regional Market Dashboard
  • 6.3. Regional Market Snapshot
  • 6.4. Regional Market Share and Leading Players, 2020
    • 6.4.1. North America
    • 6.4.2. Europe
    • 6.4.3. Asia Pacific
    • 6.4.4. Latin America
    • 6.4.5. Middle East and Africa
  • 6.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
    • 6.5.1. North America
    • 6.5.2. Europe
    • 6.5.3. Asia Pacific
    • 6.5.4. Latin America
    • 6.5.5. Middle East and Africa
  • 6.6. Market Size, & Forecasts and Trend Analysis, 2020 to 2028:
  • 6.7. North America
    • 6.7.1. U.S.
      • 6.7.1.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.7.2. Canada
      • 6.7.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
  • 6.8. Europe
    • 6.8.1. U.K.
      • 6.8.1.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.8.2. Germany
      • 6.8.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.8.3. France
      • 6.8.3.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.8.4. Italy
      • 6.8.4.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.8.5. Spain
      • 6.8.5.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.8.6. Switzerland
      • 6.8.6.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.8.7. Belgium
      • 6.8.7.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
  • 6.9. Asia Pacific
    • 6.9.1. Japan
      • 6.9.1.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.9.2. China
      • 6.9.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.9.3. India
      • 6.9.3.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.9.4. South Korea
      • 6.9.4.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.9.5. Thailand
      • 6.9.5.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.9.6. Australia
      • 6.9.6.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
  • 6.10. Latin America
    • 6.10.1. Brazil
      • 6.10.1.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.10.2. Mexico
      • 6.10.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.10.3. Argentina
      • 6.10.3.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
  • 6.11. MEA
    • 6.11.1. South Africa
      • 6.11.1.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.11.2. Saudi Arabia
      • 6.11.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
    • 6.11.3. UAE
      • 6.11.3.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competitive Categorization
    • 7.2.1. Innovators
    • 7.2.2. Market leaders
    • 7.2.3. Emerging players
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2019
  • 7.4. Public Companies
    • 7.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 7.4.2. Company market share/ranking, by region
    • 7.4.3. Competitive dashboard analysis
      • 7.4.3.1. Market differentiators
      • 7.4.3.2. Synergy analysis: major deals and strategic alliances
  • 7.5. Private Companies
    • 7.5.1. List of key emerging companies/technology disruptors/innovators
    • 7.5.2. Funding outlook
    • 7.5.3. Regional network map
    • 7.5.4. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
    • 7.5.5. Supplier ranking
    • 7.5.6. Key company profiled
    • 7.5.7. Eigen
      • 7.5.7.1. Company overview
      • 7.5.7.2. Financial performance
      • 7.5.7.3. Product benchmarking
      • 7.5.7.4. Strategic initiatives
    • 7.5.8. Koninklijke Philips N.V.
      • 7.5.8.1. Company overview
      • 7.5.8.2. Financial performance
      • 7.5.8.3. Product benchmarking
      • 7.5.8.4. Strategic initiatives
    • 7.5.9. Hitachi, Ltd.
      • 7.5.9.1. Company overview
      • 7.5.9.2. Financial performance
      • 7.5.9.3. Product benchmarking
      • 7.5.9.4. Strategic initiatives
    • 7.5.10. MedCom
      • 7.5.10.1. Company overview
      • 7.5.10.2. Financial performance
      • 7.5.10.3. Product benchmarking
      • 7.5.10.4. Strategic initiatives
    • 7.5.11. ESAOTE SPA
      • 7.5.11.1. Company overview
      • 7.5.11.2. Financial performance
      • 7.5.11.3. Product benchmarking
      • 7.5.11.4. Strategic initiatives
    • 7.5.12. KOELIS
      • 7.5.12.1. Company overview
      • 7.5.12.2. Financial performance
      • 7.5.12.3. Product benchmarking
      • 7.5.12.4. Strategic initiatives
    • 7.5.13. Focal Healthcare
      • 7.5.13.1. Company overview
      • 7.5.13.2. Financial performance
      • 7.5.13.3. Product benchmarking
      • 7.5.13.4. Strategic initiatives
    • 7.5.14. GeoScan Medical
      • 7.5.14.1. Company overview
      • 7.5.14.2. Financial performance
      • 7.5.14.3. Product benchmarking
      • 7.5.14.4. Strategic initiatives
    • 7.5.15. UC-Care Medical Systems Ltd.
      • 7.5.15.1. Company overview
      • 7.5.15.2. Financial performance
      • 7.5.15.3. Product benchmarking
      • 7.5.15.4. Strategic initiatives